GENFIT Announces Strong 2023 Financials and Progress
Company Announcements

GENFIT Announces Strong 2023 Financials and Progress

Genfit (GNFT) has released an update.

GENFIT, a biopharmaceutical company focusing on liver diseases, reported a solid financial position with €77.8 million in cash and €28.6 million in revenue for the year 2023, boosted by a milestone payment of €13.3 million. The company highlighted significant progress in its drug development, including positive Phase 3 trial results for elafibranor in PBC and the advancement of its acute-on-chronic liver failure (ACLF) program with multiple assets. GENFIT anticipates key regulatory dates and trial data in 2024, aiming to address unmet medical needs in liver disease treatment.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGENFIT’s Drug Nears EU Market Approval
TheFlyGenfit announces positive CHMP opinion for Ipsen’s Iqirvo
TipRanks Auto-Generated NewsdeskGENFIT Announces Mid-Year Liquidity Figures
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!